Rodrigues Charlene M C, Plotkin Stanley A
Department of Zoology, University of Oxford, Oxford, United Kingdom.
Department of Paediatric Infectious Diseases, St George's University Hospitals NHS Foundation Trust, London, United Kingdom.
Front Microbiol. 2020 Jul 14;11:1526. doi: 10.3389/fmicb.2020.01526. eCollection 2020.
In the 20th century, the development, licensing and implementation of vaccines as part of large, systematic immunization programs started to address health inequities that existed globally. However, at the time of writing, access to vaccines that prevent life-threatening infectious diseases remains unequal to all infants, children and adults in the world. This is a problem that many individuals and agencies are working hard to address globally. As clinicians and biomedical scientists we often focus on the health benefits that vaccines provide, in the prevention of ill-health and death from infectious pathogens. Here we discuss the health, economic and social benefits of vaccines that have been identified and studied in recent years, impacting all regions and all age groups. After learning of the emergence of SARS-CoV-2 virus in December 2019, and its potential for global dissemination to cause COVID-19 disease was realized, there was an urgent need to develop vaccines at an unprecedented rate and scale. As we appreciate and quantify the health, economic and social benefits of vaccines and immunization programs to individuals and society, we should endeavor to communicate this to the public and policy makers, for the benefit of endemic, epidemic, and pandemic diseases.
在20世纪,作为大型系统性免疫计划的一部分,疫苗的研发、许可和实施开始解决全球存在的健康不平等问题。然而,在撰写本文时,全世界所有婴儿、儿童和成人获得预防危及生命的传染病疫苗的机会仍然不平等。这是许多个人和机构正在全球努力解决的一个问题。作为临床医生和生物医学科学家,我们常常关注疫苗在预防传染病原体导致的健康不良和死亡方面所带来的健康益处。在此,我们讨论近年来已被确认和研究的疫苗在健康、经济和社会方面的益处,这些益处影响着所有地区和所有年龄组。在2019年12月得知严重急性呼吸综合征冠状病毒2(SARS-CoV-2)出现,并意识到其可能在全球传播导致冠状病毒病(COVID-19)后,迫切需要以前所未有的速度和规模研发疫苗。当我们认识到并量化疫苗和免疫计划对个人和社会在健康、经济和社会方面的益处时,我们应该努力将这些信息传达给公众和政策制定者,以应对地方病、流行病和大流行病。